About Lipoyl amidotransferase LIPT1, mitochondrial
Lipoyl amidotransferase LIPT1, mitochondrial (LIPT1) is a protein
from Homo sapiens identified by UniProt accession
Q9Y234, 373 residues long.
MolForge cross-references it against 0 known binders and
115 disease associations.
Target properties
| Protein name | Lipoyl amidotransferase LIPT1, mitochondrial |
|---|
| UniProt accession | Q9Y234 |
|---|
| Gene | LIPT1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 373 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (115)
Diseases linked to this target (Open Targets).
- lipoyl transferase 1 deficiency · score 0.78
- genetic disorder · score 0.33
- Hearing impairment · score 0.27
- Failure to thrive · score 0.27
- Abnormal cardiovascular system morphology · score 0.27
- Hypotonia · score 0.27
- Leigh syndrome · score 0.19
- FEV/FVC ratio · score 0.10
- cancer · score 0.08
- melanoma · score 0.08
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q9Y234-F1 | alphafold | PREDICTED | 91.35 | — |
Amino-acid sequence (373 residues)
MLIPFSMKNC FQLLCNCQVP AAGFKKTVKN GLILQSISND VYQNLAVEDW IHDHMNLEGK PILFFWQNSP SVVIGRHQNP WQECNLNLMR EEGIKLARRR SGGGTVYHDM GNINLTFFTT KKKYDRMENL KLIVRALNAV QPQLDVQATK RFDLLLDGQF KISGTASKIG RTTAYHHCTL LCSTDGTFLS SLLKSPYQGI RSNATASIPS LVKNLLEKDP TLTCEVLMNA VATEYAAYHQ IDNHIHLINP TDETLFPGIN SKAKELQTWE WIYGKTPKFS INTSFHVLYE QSHLEIKVFI DIKNGRIEIC NIEAPDHWLP LEIRDKLNSS LIGSKFCPTE TTMLTNILLR TCPQDHKLNS KWNILCEKIK GIM
Explore Lipoyl amidotransferase LIPT1, mitochondrial with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets